Literature DB >> 23815999

Increase in postoperative insulin requirements does not lead to decreased quality of life after total pancreatectomy with islet cell autotransplantation for chronic pancreatitis.

Margaret Dorlon1, Stephanie Owczarski, Hongjun Wang, David Adams, Katherine Morgan.   

Abstract

Previous studies have shown that total pancreatectomy with islet cell autotransplantation improves quality of life in chronic pancreatitis. A significant number of these patients develop postoperative hyperglycemia and daily insulin requirements or increase in daily insulin requirements. Our study investigates whether increased insulin requirements postoperatively have a negative impact on quality of life. A prospectively collected database of 74 patients undergoing extensive pancreatectomy with islet autotransplantation for pancreatitis was reviewed. Data pertaining to daily requirements and quality of life (QOL), as measured by the SF-12 questionnaire, in the preoperative and postoperative period were reviewed. Approval from the Institutional Review Board for the evaluation of human subjects was obtained. Seventy-four patients underwent extensive pancreatectomy with islet autotransplantation for pancreatitis. The majority of these patients required new daily insulin or an increase in daily insulin requirements postoperatively. Mean preoperative HA1c in this group was 5.6 with an increase to 7.3 at 6 months postoperatively (P < 0.001), a mean of 8.1 at 12 months, and 8.9 at 2 years. Mean preoperative daily insulin requirements for this group were five units/day with average increase to 19 units/day at 6 months, 21 units/day at 12 months, and 26 units/day at 2 years. Preoperative QOL scores were a mean of 26 for the physical component and 36 for the mental health component. Postoperatively, physical component scores averaged 33 at 6 months (p < 0.001), 36 at 12 months, and 36 at 2 years; the mental health component scores averaged 42 at 6 months (p = 0.007), 41 at 12 months, and 41 at 2 years. There is no correlation between physical component score or mental component score QOL scores and daily insulin requirements (r = -0.016 and r = 0.039, respectively). Total pancreatectomy with islet cell autotransplantation is an effective surgery for end-stage chronic pancreatitis. Quality of life significantly improves in physical and mental health components regardless of a postoperative increase in daily insulin requirements.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23815999

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  5 in total

Review 1.  Diabetes after pancreatic surgery: novel issues.

Authors:  Marina Scavini; Erica Dugnani; Valentina Pasquale; Daniela Liberati; Francesca Aleotti; Gaetano Di Terlizzi; Giovanna Petrella; Gianpaolo Balzano; Lorenzo Piemonti
Journal:  Curr Diab Rep       Date:  2015-04       Impact factor: 4.810

2.  Relief for Young Children With Severe Chronic Pancreatitis.

Authors:  Emily R Perito; Sue Rhee
Journal:  J Pediatr Gastroenterol Nutr       Date:  2017-03       Impact factor: 2.839

3.  Total pancreatectomy with islet cell auto-transplantation: update and outcomes from major centers.

Authors:  Noaman S Ali; R Matthew Walsh
Journal:  Curr Treat Options Gastroenterol       Date:  2014-09

4.  Connexin-Based Therapeutics and Tissue Engineering Approaches to the Amelioration of Chronic Pancreatitis and Type I Diabetes: Construction and Characterization of a Novel Prevascularized Bioartificial Pancreas.

Authors:  J Matthew Rhett; Hongjun Wang; Heather Bainbridge; Lili Song; Michael J Yost
Journal:  J Diabetes Res       Date:  2015-12-14       Impact factor: 4.011

5.  A new surgical technique of pancreaticoduodenectomy with splenic artery resection for ductal adenocarcinoma of the pancreatic head and/or body invading splenic artery: impact of the balance between surgical radicality and QOL to avoid total pancreatectomy.

Authors:  Ryosuke Desaki; Shugo Mizuno; Akihiro Tanemura; Masashi Kishiwada; Yasuhiro Murata; Yoshinori Azumi; Naohisa Kuriyama; Masanobu Usui; Hiroyuki Sakurai; Masami Tabata; Shuji Isaji
Journal:  Biomed Res Int       Date:  2014-06-12       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.